Greater Cannabis Company (GCAN) Total Non-Current Liabilities (2016 - 2021)
Greater Cannabis Company's (GCAN) quarterly Total Non-Current Liabilities came in at $460651.0 in Q1 2021, down 53.71% year-on-year from $995119.0 in Q1 2020, and up 4.11% quarter-over-quarter from $442467.0 in Q4 2020.
Greater Cannabis Company (GCAN) Total Non-Current Liabilities (2016 - 2021) Analysis & Trends
Greater Cannabis Company's Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $460651.0 for Q1 2021.
- On a quarterly basis, Total Non-Current Liabilities fell 53.71% year-over-year to $460651.0 in Q1 2021; TTM through Mar 2021 was $460651.0, a 53.71% decrease from a year earlier, with the FY2020 full-year figure at $442467.0, down 72.03% from the prior year.
- Total Non-Current Liabilities grew to $460651.0 in Q1 2021 per GCAN's latest filing, from $442467.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.6 million in Q4 2019 and bottomed at -$205403.0 in Q4 2017.
- The 5-year median for Total Non-Current Liabilities is $459956.0 (2019), against an average of $517437.2.
- Across the five-year window, Total Non-Current Liabilities sank 2437.31% in 2017 and soared 394.54% in 2018, its largest moves.
- Year by year, Total Non-Current Liabilities stood at -$205403.0 in 2017, then jumped by 394.54% to $604999.0 in 2018, then jumped by 161.46% to $1.6 million in 2019, then slumped by 72.03% to $442467.0 in 2020, then gained by 4.11% to $460651.0 in 2021.
- Per Business Quant, the three latest GCAN Total Non-Current Liabilities figures stand at $460651.0 (Q1 2021), $442467.0 (Q4 2020), and $599261.0 (Q3 2020).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Greater Cannabis Company | 292,929.85 | 292,929.85 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 460,651.00 |
| Dec 31, 2020 | 442,467.00 |
| Sep 30, 2020 | 599,261.00 |
| Jun 30, 2020 | 774,453.00 |
| Mar 31, 2020 | 995,119.00 |
| Dec 31, 2019 | 1.58 Mn |
| Sep 30, 2019 | 508,947.00 |
| Jun 30, 2019 | 459,956.00 |
| Mar 31, 2019 | 409,882.00 |
| Dec 31, 2018 | 604,999.00 |
| Sep 30, 2018 | 401,874.00 |
| Jun 30, 2018 | 274,624.00 |
| Mar 31, 2018 | 217,776.00 |
| Dec 31, 2017 | -205,403.00 |
| Sep 30, 2017 | 235,097.00 |
| Dec 31, 2016 | 8,788.00 |